Patterns of markers of inflammation, coagulation and vasoconstriction during follow-up of abdominal aortic aneurysms

International Angiology

Volumn 31, Issue 3, 2012, Pages 276-282

  Flondell Site D ^a   Lindblad, B ^a   Gottsater A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Aortic aneurysm, abdominal; CD40 ligand; Endothelin 1; Growth; Interleukin 6; Tumour necrosis factor alpha

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CD40 LIGAND; ENDOTHELIN 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 3; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; AGED; ANEURYSM SURGERY; ARTICLE; BLOOD CLOTTING; CONSERVATIVE TREATMENT; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; TREATMENT DURATION; VASOCONSTRICTION;

AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; PROSPECTIVE STUDIES; VASOCONSTRICTION;

EID: 84864780409     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Heinecke J et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 2001;34:730-8.
2. Vainas T, Lubbers T, Stassen FR, Herngreen SB, van Dieijen-Visser MP, Bruggeman CA et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003;107:1103-5.
3. Lindblad B, Börner G, Gottsäter A. Factors associated with development of large abdominal aortic aneurysm in middle-aged men. Eur J Vasc Endovasc Surg 2005;30:346-52.
4. Lindholt JS, Shi G-P. Chronic inflammation, immune response and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006;31:453-63.
5. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm pathogenesis and implications for management. Art Thromb Vasc Biol 2006, 26:2605-19.
6. Schlösser FJV, Tangelder MJD, Verhagen HJM, van der Heijden GJMG, Muhs BE, van der Graaf Y et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008;47:1127-33.
7. Urbonavicius S, Urbonaviciene G, Honoré B, Henneberg EW, Vorum H, Lindholt JS. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture - a systematic review. Eur J Vasc Endovasc Surg 2008;36:273-80.
8. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, Yano Y et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008;102:1368-77.
9. Mäyränpää MI, Trosien JA, Fontaine V, Folkesson M, Kazi M, Eriksson P et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. J Vasc Surg 2009;50:388-95.
10. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Savers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007;45:574-80.
11. Hamano K, Li TS, Takahashi M, Kobayashi T, Shirazawa B, Ito H et al. Enhanced tumour necrosis factor- alpha expression in small sized abdominal aortic aneurysms. World J Surg 2003;27:476-80.
12. Dawson J, Cockerhill GW, Choke E, Belli AM, Loftus I, Thompson MM. Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg 2007;45:350-6.
13. Flondell-Sité D, Lindblad B, Kölbel T, Gottsäter A. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokine 2009;46:211-5.
14. Kälsch T, Nguyen XD, Elmas E, Grebert N, Süselbeck T, Klüter H et al. Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol 2006;111:217-23.
15. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-103.
16. Schönbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U et al. Oxidized low-density lipoprotein augments and 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002;106:2888-93.
17. Newby DE, Webb DJ. The endothelin system in cardiovascular disease. Br Med J 1997;314:531-2.
18. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997;29:65-9.
19. Třeška V, Wenham PJ, Valenta J, Topolčan O, Pecen L. Plasma endothelin levels in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1999;17:424-8.
20. Wagner A, Domanovits H, Holzer M, Kofler J, Röggla M, Müllner M et al. Plasma endothelin in patients with acute aortic disease. Resuscitation 2002;53:71-6.
21. Flondell-Sité D, Lindblad B, Gottsäter A. High levels of endothelin (ET)-1 and aneurysm diameter independently predict growth of stable abdominal aortic aneurysms. Angiology 2010;61:324-8.
22. Flondell-Sité D, Lindblad B, Kölbel T, Gottsäter A. Markers of proteolysis, fibrinolysis and coagulation in relation to size and growth rate of abdominal aortic aneurysm. Vasc Endovasc Surg 2010;44:262-8.
23. Yamazumi K, Ojiro M, Okumura H, Aikou T. An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. Am J Surg 1998;175:297-301.
24. Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001;86:604-10.
25. Kölbel T, Strandberg K, Mattiasson I, Stenflo J, Lindblad B. Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg 2006;43:935-9.
26. Kölbel T, Strandberg K, Donath T, Mattiasson I, Stenflo J, Lindblad B. Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate? Vasc Endovasc Surg 2008;42:135-40.
27. Singh K, Jacobsen BK, Solberg S, Bønaa KH, Kumar S, Bajic R et al. Intra- and interobserver variability in the measurements of abdominal aortic and common iliac artery diameter with computed tomography. The Tromso study. Eur J Vasc Endovasc Surg 2003;25:399-407.
28. Kölbel T, Donath T, Strandberg K, Flondell-Sité D, Kühme T, Gottsäter A, Lindblad B. Is increased thrombin activation in patients with abdominal aortic aneurysms dependent on area or volume of aneurysm thrombus mass? Angiology 2010;61:113-8.
29. Barton M. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2000;2:84-91.
30. Nilsson LM, Sun ZW, Nilsson J, Nordström I, Chen YW, Molkentin JD et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2007;292:C1167-78.
31. Gottsäter A, Flondell-Sité D, Kölbel T, Lindblad B. Associations between statin treatment and markers of inflammation, vasoconstriction and coagulation in patients with abdominal aortic aneurysm. Vasc Endovasc Surg 2009;42:567-73.
32. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006;32:21-6.
33. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of adominal aortic aneurysm at long term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006;97:279-80.
34. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 1999;29:130-8
35. Thompson RW, Baxter T. MMP inhibition in abdominal aortic aneurysms: rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999,878:159-78.
36. Nagashima H, Aoka Y, Sakomura Y, Uto K, Sakuta A, Aomi S et al. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg 2004;39:447-53.
37. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 2009;183:2741-6.
38. Treska V, Topolcan O, Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chemi Lab Med 2000;38:1161-4.
39. Szekanecz Z, Shah MR, Pearce WH and Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions 1994;42:159-62.
40. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48-54.
41. Armstrong PJ, Franklin DP, Carey DJ and Elmore JR. Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg 2005;19:248-57.
42. Thompson AR, Cooper JA, Ashton HA, Hafez H. Growth rates of small abdominal aneurysms correlate with clinical events. Br J of Surgery 2010;97:37-44.